Acute myeloid leukemia (AML) represents a heterogeneous group of hematological neoplasms associated with the accumulation of acquired genetic and epigenetic aberrations in hematopoietic progenitor cells. Myeloid leukemogenesis is directly linked to the disruption of expression of transcription factors that regulate the proliferation, survival and differentiation of myeloid progenitors. Moreover, overexpression of particular genes has been associated with prognosis in AML, enabling patients with different survival rates to be identified within cytogenetic risk groups. The GATA2 gene encodes a transcription factor that mediates essential functions in hematopoietic stem cell and progenitor cell (HSC/HPC) compartments. The essential role of GATA2 in hematopoiesis is evident in mice lacking GATA2, which are anemic, have fewer HSC/HPC cells and that die by day 10-11 of gestation. 1 Expression of GATA2 is critical at various stages of hematopoiesis, and as it in part determines the fate of distinct myeloid lineages, GATA2 expression is tightly regulated. Indeed, ectopic expression of GATA2 has been reported to promote erythroblast proliferation while blocking terminal erythroid differentiation. 2 Furthermore, alterations in GATA2 expression have been observed in patients with myelodysplastic syndrome, where it has been related to severe dysplasia. 3 Nevertheless, to date, only two studies have analyzed the expression of GATA2 in AML. Strong GATA2 expression was found in 87% of AML patients (54/62) using single-round RT-PCR. 4 More recently, Ayala et al. 5 analyzed the expression of GATA2 in 41 patients with AML by real-time quantitative RT-PCR (QRT-PCR). They found that 21 cases had expression of GATA2 (52%), and defined overexpression as the expression values that were over the median value in GATA2-expressing patients. Therefore, to further clarify the significance of GATA2 overexpression in AML, we investigated its prevalence in a large series of AML patients using QRT-PCR. Furthermore, using an established cutoff value, we correlated these results with cytogenetic data and molecular markers, and we determined the prognostic relevance of GATA2 expression levels. GATA2 expression was analyzed in bone marrow samples from 259 AML patients referred for analysis to the University of Navarra (Spain). Gene expression was quantified using the ABI Prism 7500 Real Time PCR System and TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA), with GAPDH as an internal control. A gene was considered to be overexpressed if its expression level was greater than the established cutoff value determined for each gene (mean±3 s.d.), defined by the analysis of 10 bone marrow samples from normal donors. Statistical analyses were performed using the SPSS software package (v.15, SPSS Inc., Chicago, IL, USA). More detailed information about the molecular and statistical analyses performed is provided in the Supplementary Information.
Using the calculated cutoff value for GATA2 expression, we divided patients into two groups: 'cases with overexpression of GATA2' and 'cases with no GATA2 overexpression'. With this approach, we found that GATA2 was overexpressed in 37.4% of cases (97/259), suggesting that this could be a recurrent event in AML (Table 1 and Supplementary Figure 1) . Thus, for the first time we showed the prevalence of GATA2 overexpression in a large cohort of AML patients using QRT-PCR. The possible association between GATA2 expression and other biological features was analyzed using the w 2 -test or the Fisher's exact test, as appropriate, for categorical variables, and the Mann-Whitney test for continuous variables. We found that GATA2 overexpression was associated with clinical and biological features that confer poor prognosis in AML. Accordingly, GATA2 overexpression was more prevalent in the poor cytogenetic risk group (46%), in elderly patients (P ¼ 0.056), in those with secondary AML (P ¼ 0.054), and in patients overexpressing WT1 (Po0.001) and EVI1 (Po0.001) ( Table 1 ). These data support previous findings demonstrating a role for GATA2 as an enhancer of WT1 transcription, and describing a positive correlation between GATA2 and WT1 messenger RNA (mRNA) levels. 6 Furthermore, EVI1 has been shown to bind directly to the GATA2 promoter and act as an enhancer, suggesting that GATA2 represents a critical target of EVI1. 7 High levels of GATA2 expression have been associated with myeloid neoplasms involving 3q rearrangements. 8 When we analyzed the 20 patients with 3q rearrangements by fluorescence in situ hybridization, EVI1 was overexpressed in the nine patients with 3q21 and/or 3q26 aberrations (two 3q21 rearrangements, six 3q26 and one 3q21q26). With the exception of two cases with 3q26 aberrations, GATA2 was overexpressed in seven of these nine cases. Thus, the majority of patients overexpressed both GATA2 (3q21) and EVI1 (3q26) (7/9, 77.8%). These data would indicate that GATA2 contributes as a downstream target gene of EVI1 to the leukemic transformation of EVI1-positive AML, an issue that merits further investigation.
In the intermediate cytogenetic risk group, cases that overexpressed GATA2 were overrepresented in the subgroup of patients with a normal karyotype (NK)-AML (43 vs 14%; P ¼ 0.002), which prompted us to analyze this cohort at the molecular level. We found that GATA2 overexpression was associated with FLT3-ITD (P ¼ 0.017) and NPM1 mutations (P ¼ 0.001), and with WT1 (P ¼ 0.005) and EVI1 overexpression (P ¼ 0.004) ( Table 2 ). Recent data have suggested that screening for CEBPA-double mutations can be restricted to patients with intermediate-risk cytogenetics and with no mutations in FLT3 or NPM1, and that only the presence of a CEBPA-double mutation should be used for therapeutic risk stratification. 9 In cases where we had material left, we found that five exhibited a FLT3 wt/NPM1 wt/CEBPA-mutated genotype (four with single mutations and one with double mutations in CEBPA). Although GATA2 was not overexpressed in any of these five cases, these results do not preclude an association between CEBPA mutations and GATA2 expression. We next quantified GATA2 expression in two independent series of bone marrow samples from NK-AML patients (Supplementary Table 1 ). According to our cutoff value, GATA2 was overexpressed in 59.5% (25/42) and 44% (25/57) of NK-AML patients, percentages that were even higher than the percentage found in our initial AML series. In both cohorts, GATA2-overexpressing cases were more frequent in patients with FLT3-ITD, although this association was not statistically significant (Supplementary Table 1 ). These results underline the need to analyze larger series of NK-AML patients. To investigate whether GATA2 was also overexpressed at protein level, western blot analyses were carried out in 11 NK-AML patient samples, 6 of which had GATA2 overexpression according to our established cutoff value. Western blot analyses confirmed high GATA2 protein expression in these six cases, and showed a good correlation between expression and protein levels in all cases analyzed (Supplementary Figure 2) . Furthermore, GATA2 was overexpressed in 5 out of 11 AML cell lines (HL-60, HEL, TF-1, F36-P and KG-1), both at the mRNA and protein level (Supplementary Figure 3) . Thus, our results in both patient samples and cell lines demonstrate a good correlation between GATA2 mRNA overexpression and protein levels.
We next analyzed the prognostic significance of GATA2 expression in AML, excluding the patients with acute promyelocytic leukemia from this analysis. From the total number of AML cases, 112 patients were treated according to the Spanish PETHEMA co-operative group protocol LAM/99 (http:clinicaltrials.gov/, identifiers: NCT00464217 and NCT00390715. Detailed information is included in the Supplementary Information). The prognostic value of GATA2 overexpression was first analyzed in these 112 patients (Supplementary Table 2 ), examining the estimated probabilities of overall survival (OS), disease-free survival (DFS) and eventfree survival (EFS) calculated using the Kaplan-Meier method, and evaluating the differences between survival distributions using the log-rank test. The median age at diagnosis of this cohort was 57 years (range 14-83), and the male to female ratio was B1:1. The median follow-up of the cohort was 188 weeks Table 1 Prevalence of GATA2 overexpression in 259 patients with acute myeloid leukemia at diagnosis, and its association with cytogenetic and molecular markers Table 2 ). Outcome analyses revealed that the patients overexpressing GATA2 had a significantly lower OS (P ¼ 0.007) and EFS (P ¼ 0.006), and that they tended towards a lower DFS (P ¼ 0.058) than patients with normal GATA2 expression (Figure 1 ). In this series (n ¼ 112), GATA2 expression levels ranged from 0.01 to 56.09 (mean ¼ 4.41, median ¼ 1.53). As a continuous variable, GATA2 expression had a prognostic impact on survival: OS (P ¼ 0.009), DFS (P ¼ 0.032) and EFS (P ¼ 0.034). Indeed, 71.8% of patients with normal GATA2 expression achieved complete remission (CR, 51/71), as compared with only 58% of those overexpressing GATA2 (22/38), although this association was not statistically significant (P ¼ 0.140). When the prognostic value of GATA2 expression was assessed previously in a cohort of 36 AML patients, there was no difference in either OS or EFS between groups with and without GATA2 expression, or groups that overexpressed GATA2 or not. However, the small sample size used in this study highlights the need for further studies. 5 Using a Cox proportional hazards model, we next assessed the influence of distinct baseline variables on OS, DFS and EFS: age, sex, bone marrow blasts at diagnosis, white blood count at diagnosis, AML type, FLT3-ITD and NPM1 mutations, and GATA2 expression groups (Supplementary Table 3) . Notably, multivariate analyses demonstrated that GATA2 overexpression CEBPA mutation analyses were performed in normal karyotype cases lacking FLT3-ITD and NPM1 mutations. c Variables were dichotomized based on the calculated cutoff value. Significant results are highlighted in bold.
Letters to the Editor was an unfavorable independent prognostic factor associated with shorter OS when adjusted for age and cytogenetic prognostic group (hazard ratio ¼ 1.66; 95% CI ¼ 1.05-2.64; P ¼ 0.029) (Supplementary Table 3 ). As indicated above, we observed a significant association between GATA2 overexpression and WT1. WT1 is a useful marker in the assessment of minimal residual disease, enabling cohorts of patients with a higher risk of relapse to be identified. 10 Thus, we hypothesized that GATA2 expression could define a group of patients with a worse prognosis among those overexpressing WT1 (89 cases). Indeed, GATA2 overexpression identified a group of patients with a lower OS (P ¼ 0.002) and EFS (P ¼ 0.001) compared with those expressing normal levels of GATA2 (Supplementary Figure  4) . Further studies will be necessary to investigate the potential association between GATA2 and WT1 expression in assessing the minimal residual disease in AML.
As GATA2 overexpression was significantly more common in patients with a NK, we investigated the prognostic impact of GATA2 expression in this cohort. Follow-up data were only available for 57 NK-AML patients. The median age at diagnosis of this cohort was 61 years (range ¼ 28-76), with a male to female ratio of B1:1. The median follow-up in the cohort was 174 weeks (range ¼ 21-314), and the median OS was 47 weeks (95% CI ¼ 28.8-65.1). The estimated cumulative proportion of surviving patients was 63.1% at 26 weeks and 22.9% at 103 weeks. In this series, GATA2 was overexpressed in 23 cases (40%) (Supplementary Table 4 ). As expected, we found significant differences in the OS of patients with FLT3 wild type (wt) vs FLT3-ITD (P ¼ 0.038). No such effect was observed when comparing cases with NPM1 wt vs NPM1 mutated in the FLT3 wt group, probably due to the small sample size. Outcome analyses revealed that NK-AML patients overexpressing GATA2 had a lower OS (P ¼ 0.024), DFS (P ¼ 0.006) and EFS (P ¼ 0.034) than those with normal GATA2 expression (Supplementary Figure 5) . In this cohort, GATA2 expression ranged from 0.01 to 56.09 (mean ¼ 5.26, median ¼ 2.00). As a continuous variable, GATA2 expression had a significant prognostic impact on OS (P ¼ 0.023) and DFS (P ¼ 0.019), and a nearly significant impact on EFS (P ¼ 0.076). Interestingly, among patients with the FLT3 wt/NPM1-mutated genotype (n ¼ 18), those overexpressing GATA2 had a lower OS (P ¼ 0.037), DFS (P ¼ 0.041) and EFS (P ¼ 0.013) than patients with normal GATA2 expression. These results indicate that GATA2 expression may distinguish a subgroup within this genotype with a poorer prognosis. However, to validate this hypothesis, it will be necessary to confirm these observations in a larger series of patients.
To further determine the relevance of GATA2 expression as a prognostic marker in AML, we reanalyzed a large gene expression dataset published previously (publicly available in the Gene Expression Omnibus database, accession number GSE425). 11 Normalized fluorescence ratios (ratio of the specimen value to the reference value) of well-measured spots were used in this analysis. 11 To correlate this information with survival data, GATA2 expression was categorized as 'high' and 'low' GATA2 expression, referring to levels of expression above and below the 75th percentile value of the expression in all the AML samples, respectively. The impact of GATA2 expression was first analyzed in the whole population, excluding cases with acute promyelocytic leukemia (103 patients, 98 with wellmeasured fluorescence ratios for GATA2). OS was significantly lower in patients with high GATA2 expression (24 cases) than in those with low GATA2 expression (74 cases, P ¼ 0.001). Furthermore, of the 40 NK-AML cases with well-measured fluorescence ratios for GATA2, those with high GATA2 expression (n ¼ 14) had poorer outcomes than the patients with low GATA2 expression (n ¼ 26, P ¼ 0.024). Moreover, in the NK-AML cohort, FLT3-ITD mutations were more frequent in patients with high rather than low levels of GATA2 expression (78.6 vs 45.8%, respectively; P ¼ 0.049). Notably, two prognostically relevant subgroups within the NK-AML cohort of this series were identified, and high levels of expression of GATA2 were found in the group with the worst prognosis.
11 Figure 1 Survival analysis according to GATA2 overexpression status. Kaplan-Meier analyses of 112 patients with AML show that cases with GATA2 overexpression had a significantly inferior OS, EFS, and tended to have worse DFS than patients with no GATA2 overexpression.
In conclusion, for the first time we report a large series of patients in which overexpression of GATA2 is a recurrent event associated with a poor outcome in AML. We also confirmed GATA2 overexpression at the protein level. GATA2 overexpression was significantly associated with FLT3-ITD mutations in patients with a NK, suggesting that these may represent cooperative events in AML. Our data indicate that GATA2 overexpression may be a useful molecular marker for predicting clinical outcome in AML. However, further studies will be required to elucidate the biological consequences of the overexpression of this transcription factor.
